PCVX (vaxcyte.com) Net earnings per share (EPS TTM)

vaxcyte.com (PCVX) - corporate logo

Exclusive patents for cell-free vaccine synthesis create an insurmountable barrier for Vaxcyte, Inc. (PCVX), as confirmed by the current trailing twelve-month net income per share, where the status is -8.15. The asset is shielded from economic crises, although it remains subject to seasonal demand fluctuations. The large-scale implementation of robotic bioreactors minimizes drug contamination risks, optimizing production cycles.

PCVX (SutroVax) Net earnings per one share for the last twelve months history from 07/04/2022 to 11/14/2026

Vaxcyte Inc (PCVX) - metric breakdowns and financial figures

- current quotes and average value forecast:
Price Chart Vaxcyte, Inc.|PCVX - Broker Consensus Forecast
- business market valuation indicators:
Market Capitalization Vaxcyte, Inc.|PCVX - Full Business Value
- business book valuation details:
Book Value per Share Vaxcyte|PCVX - Total Stockholders' Equity|Market Capitalization to Book Value Ratio vaxcyte.com|PCVX - Cumulative Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Vaxcyte, Inc.|PCVX - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Vaxcyte Corp|PCVX - Company Total Debt Obligations|Debt to Book Capitalization Ratio Vaxcyte, Inc.|PCVX - Long-Term Debt|Company Short-Term Debt Vaxcyte|Quick Liquidity vaxcyte.com
- net income and valuation multiples indicators:
PCVX - Net Financial Result|Future Profit Vaxcyte, Inc.|PCVX - Price to Earnings Ratio|Forward P/E Multiple Vaxcyte|PCVX - PEG Multiple|Enterprise Value to EBITDA Ratio Vaxcyte, Inc.|PCVX - Operating profit before amortization|Net earnings per share (EPS TTM) Vaxcyte|PCVX - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months vaxcyte.com|PCVX - Earnings per share growth rate in current year|Expected earnings per share growth for next year Vaxcyte, Inc.
- revenue and sales proceeds data:
PCVX - Company Total Sales|Projected Sales Volume Vaxcyte, Inc.|PCVX - Price to Sales|Forward Price-to-Revenue Multiple Vaxcyte, Inc.
Fundamental company analysis:PCVX - Vaxcyte, Inc.
Flagship merchandise of Vaxcyte Inc

For the conservative investor, the change in TTM net income per share serves as an objective measure of real business efficiency, dividing the company's total profit by the total number of securities. In the case of Vaxcyte, Inc. (PCVX), this metric reflects financial stability during the development of multivalent vaccines, where pipeline diversification minimizes the risks of individual trials, ensuring the long-term fundamental value of the asset.

Main competitors

SMMT - Earnings per share for the last twelve months|MRNA (modernatx.com) - Earnings per share for the last 12 months|TARS: Net earnings per share (EPS TTM)|Earnings per one share for the last 12 months CRMD (CorMedix Inc)|MCRB (Seres) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Spero Pharma SPRO|Net earnings per share (EPS TTM) SCYX|Net earnings per share for the last 12 months an2therapeutics.com ANTX|PolyPid - Net earnings per share for the last 12 months|Earnings per share for the last four quarters LSB (LakeShore Biopharma Co., Ltd.)|Iterum Therapeutics, plc - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters BiomX Inc. PHGE|soligenix.com (SNGX) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months 60 Degrees Pharmaceuticals, Inc. (SXTP)|Earnings per share for the last twelve months Oragenics|Earnings per share for the last 12 months OPGN (OpGen Inc)